

# Effects of Exercise and Lifestyle Intervention on Cardiovascular Function in CKD

Erin J. Howden,<sup>\*†</sup> Rodel Leano,<sup>†</sup> William Petchey,<sup>\*\*</sup> Jeff S. Coombes,<sup>\*†</sup> Nicole M. Isabel,<sup>\*\*</sup> and Thomas H. Marwick<sup>§</sup>

## Summary

**Background and objectives** CKD is associated with poor cardiorespiratory fitness (CRF). This predefined substudy determined the effect of exercise training and lifestyle intervention on CRF and explored the effect on cardiovascular risk factors and cardiac and vascular function.

**Design, setting, participants, & measurements** Between February 2008 and March 2010, 90 patients with stage 3–4 CKD were screened with an exercise stress echocardiogram before enrollment. Patients ( $n=83$ ) were randomized to standard care (control) or lifestyle intervention. The lifestyle intervention included multidisciplinary care (CKD clinic), a lifestyle program, and aerobic and resistance exercise training for 12 months. CRF (peak  $\dot{V}O_2$ ), left ventricular function, arterial stiffness, anthropometric, and biochemical data were collected at baseline and 12 months.

**Results** Ten percent of randomized patients had subclinical myocardial ischemia at screening and completed the study without incident. There was no baseline difference among 72 patients who completed follow-up (36 in the lifestyle intervention group and 36 in the control group). The intervention increased peak  $\dot{V}O_2$  ( $2.8 \pm 0.7$  ml/kg per minute versus  $-0.3 \pm 0.9$  ml/kg per minute;  $P=0.004$ ). There was small weight loss ( $-1.8 \pm 4.2$  kg versus  $0.7 \pm 3.7$  kg;  $P=0.02$ ) but no change in BP or lipids. Diastolic function improved (increased  $e'$  of  $0.75 \pm 1.16$  cm/s versus  $-0.47 \pm 1.0$  cm/s;  $P=0.001$ ) but systolic function was well preserved and did not change. The change in arterial elastance was attenuated ( $0.11 \pm 0.76$  mmHg/ml versus  $0.76 \pm 0.96$  mmHg/ml;  $P=0.01$ ).  $\Delta$  peak  $\dot{V}O_2$  was associated with group allocation and improved body composition.

**Conclusions** Exercise training and lifestyle intervention in patients with CKD produces improvements in CRF, body composition, and diastolic function.

*Clin J Am Soc Nephrol* 8: 1494–1501, 2013. doi: 10.2215/CJN.10141012

## Introduction

Patients with CKD have increased prevalence of cardiovascular disease (CVD), which is the leading cause of mortality and morbidity in this population (1). Obesity, type 2 diabetes, and hypertension are common, and contribute to the progression of kidney dysfunction and cardiovascular risk. Conventional treatment strategies are only partially effective in improving outcomes and are frequently underutilized (2). Alternate strategies to address these risks are required. CKD patients have reduced cardiorespiratory fitness (CRF) compared with the general population (3), and those CKD patients who are inactive (4) have an increased risk of mortality. Exercise can be effective in management of cardiovascular risk factors (5,6); however, there are few long-term exercise studies in the CKD population (7).

Abnormal left ventricular (LV) structure (LV hypertrophy and dilation) and impaired diastolic and systolic function are strongly associated with morbidity and mortality in ESRD (8). Patients with early CKD have relatively preserved systolic function but demonstrate increased risk of diastolic dysfunction

(9). Newer echocardiographic techniques such as tissue Doppler imaging provide information about myocardial tissue velocities associated with relaxation ( $e'$ ) and contraction ( $s'$ ) of the LV. Two-dimensional speckle tracking imaging allows the determination of myocardial deformation or change in length of the myocardial fiber over time, referred to as global strain and strain rate. Global strain has been shown to be a powerful independent predictor of mortality in patients with preserved systolic function (10), and is reduced in patients with CKD.

There is increasing recognition of the importance of the bidirectional interaction between the arterial system and the heart (“ventricular-vascular coupling”). This matching ensures that cardiac performance is optimized during physiologic stress. Effective arterial elastance ( $E_A$ ) measures the net arterial load imposed on the LV. LV end systolic elastance ( $E_{LV}$ ) is a load-independent measure of LV performance. At rest,  $E_A/E_{LV}$  is maintained within a narrow range in healthy individuals, allowing the optimal transfer of blood from the LV to the periphery. Patients with CKD are at risk of increased vascular stiffness *via*

<sup>\*</sup>Schools of Human Movement Studies, University of Queensland, Queensland, Australia; <sup>†</sup>Centre for Clinical Research Excellence—Cardiovascular Disease and Metabolic Disorders, University of Queensland, Queensland, Australia; <sup>\*\*</sup>Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia; and <sup>§</sup>Menzies Research Institute, Tasmania, Australia

<sup>†</sup>Department of Renal Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia; and <sup>§</sup>Menzies Research Institute, Tasmania, Australia

## Correspondence:

Dr. Nicole Isabel, Renal Research, Department of Nephrology, Princess Alexandra Hospital, Ipswich Road, Brisbane, Queensland, 4102, Australia. Email: nikky\_isbel@health.qld.gov.au

multiple mechanisms (hypertension, diabetes, vascular calcification). Therefore, resting LV filling pressure is increased and LV contractility is enhanced in CKD in order to maintain  $E_A/E_{LV}$  and cardiac performance (11). Unfit individuals have less favorable cardiac filling profiles at rest than active participants (12), and exercise training can elicit positive changes in diastolic (13) and vascular function (14) in patients with existing CVD.

The aim of this study was to investigate the effect of exercise training and lifestyle intervention on CRF (change in peak  $\dot{V}O_2$  at 12 months), secondary aims were to assess the effect on cardiovascular risk factors, cardiac function, arterial stiffness, and ventricular-vascular interaction in CKD.

## Materials and Methods

### Patient Selection

Detailed methods are available in the Supplemental Material. This study was a prespecified substudy of an ongoing open-label randomized controlled trial (LANDMARK III), which is a 3-year study comparing the effect of a nurse practitioner–led model of care with standard nephrologic care on cardiovascular risk factors. The study received approval from the Princess Alexandra Human Research Ethics Committee (HREC 2007/190) and University of Queensland Medical Research Ethics Committee (MREC 2008000184), and was registered at [www.anzctr.org.au](http://www.anzctr.org.au) (Registration Number ANZCTR 12608000337370). Patients were eligible for inclusion if they were aged 18–75 years, had moderate CKD (estimated GFR [eGFR] 25–60 ml/min per 1.73 m<sup>2</sup>), and had one or more uncontrolled cardiovascular risk factors such as BP exceeding target, overweight (body mass index [BMI] >25 kg/m<sup>2</sup>), poor diabetic control (hemoglobin A1c >7%), or lipids exceeding target. Exclusion criteria were as follows: intervention for or symptomatic coronary artery disease (within 3 months), current heart failure (New York Heart Association class III and IV) or significant valvular heart disease, pregnant or planning to become pregnant, and life expectancy or anticipated time to dialysis or transplant <6 months. Participants provided written informed consent and the study complied with the Declaration of Helsinki.

### Outcomes

The primary outcome of this substudy was change in CRF (as measured by peak  $\dot{V}O_2$ ) at 12 months. Secondary outcomes were change in cardiovascular risk factors (weight, BP, lipids), cardiac function (measured by systolic [s'] and diastolic [e'] tissue velocity), arterial stiffness (augmentation index and aortic pulse wave velocity), and ventricular-vascular coupling (arterial and ventricular elastance).

### Baseline Assessment and Random Assignment

Patients were screened for inducible myocardial ischemia by exercise stress echocardiography (ESE). Patients with an abnormal ESE were reviewed by a cardiologist and randomized if deemed safe to participate in a supervised exercise program. Patients were assigned to either the lifestyle intervention group or to the usual care control group in a 1:1 ratio using a computer random assignment program. Groups were stratified by renal function (eGFR

high [ $>44$ ] or low [ $\leq 44$ ] ml/min per 1.73 m<sup>2</sup>), sex, and diabetes status.

### Control Group

The control group received standard nephrologic care, which included review by a nephrologist, recommended lifestyle modification but no specific information or education, and referral to an allied health professional on an *ad hoc* basis.

### Exercise Training and Lifestyle Intervention

In addition to usual care, cardiovascular risk factor management was provided by a multidisciplinary clinic (including a CKD nurse practitioner, dietitian, exercise physiologist, diabetic educator, psychologist, and social worker) and targeted risk factors to national guidelines (15,16).

The exercise training component involved 150 minutes of moderate intensity exercise per week, with 8 weeks of training supervised by an accredited clinical exercise physiologist. Patients attended gym sessions two to three times per week. The sessions included a warm-up, 20–30 minutes of aerobic activity using a treadmill, stationary bike, or rowing ergometer, and whole-body resistance training with machines and free weights. On completion of the gym-based training, patients began a home-based program and were provided a booklet depicting resistance exercise using Thera-Bands and a Swiss ball. Regular contact was maintained *via* telephone and Email. Participants were questioned on their ability to maintain the prescribed exercise; if they identified difficulty, they were encouraged to attend gym-based refresher visits. Patients performed exercise at a moderate intensity, with perceived exertion of 11–13 on the 20-point Borg scale (17), and progression was tailored individually.

Lifestyle intervention involved 4 weeks of group behavior and lifestyle modification facilitated by a dietitian and psychologist. The program focused on sustainable diet and behavior change to assist with weight loss. The dietitian therapy complied with the Evidence-Based Practice Guidelines for Nutritional Management of CKD for patients with eGFR between 25 and 60 ml/min per 1.73 m<sup>2</sup> (18).

### Outcome Measures

All measures were obtained before randomization and after 12 months of intervention.

**Biochemical Analyses.** After an overnight fast, patients provided blood samples for biochemical analysis. Kidney function was determined as the eGFR using the Modified Diet in Renal Disease formula based on the isotope dilution mass spectrometry standardized creatinine assay (MDRD<sub>175</sub>) (19).

**Maximal Exercise Capacity.** CRF was assessed as peak  $\dot{V}O_2$ . Testing was performed according to American College of Sports Medicine guidelines for exercise testing (20). CRF was derived from breath-by-breath indirect calorimetry (Vmax29c; SensorMedics, Yorba Linda, CA) and recorded as the peak 20-second average  $\dot{V}O_2$  during the final minute of exercise.

**Echocardiography.** Conventional two-dimensional echocardiography and pulse wave tissue Doppler imaging was performed at rest using standard equipment (Vivid 7;

General Electric Medical Systems, Milwaukee, WI). All echocardiographic parameters were measured offline in batches by an observer blinded to treatment allocation and previous results.

**Evaluation of Diastolic and Systolic Function.** Systolic dysfunction was identified on the basis of an ejection fraction  $<50\%$ . Diastolic dysfunction was categorized as normal diastolic function, delayed relaxation (21), pseudo normal (22,23), or restrictive diastolic filling (24).

**Arterial Compliance.** Arterial waveforms were acquired as previously published (25) using commercial software (SphygmoCor 8.1; AtCor Medical, Sydney, Australia). Central arterial stiffness was estimated in duplicate by aortic pulse wave velocity (PWV). PWV was acquired with electrocardiography-gated sequential tonometry at the carotid and femoral sites.

**Ventricular-Vascular Interaction.** Measures were derived noninvasively using a combination of echocardiography for end systolic volume (ESV) and tonometry for end systolic pressure (ESP). Arterial elastance ( $E_A$ ) was calculated as the ratio of ESP and stroke volume (SV)  $E_A = (ESP/SV)$ , and end systolic elastance ( $E_{LV}$ ) was calculated  $E_{LV} = (ESP/ESV - V_0)$ , where  $V_0$  is the  $x$ -axis intercept of the pressure-volume relationship (26). The value of  $V_0$  is considered to be negligible compared with ESV and is therefore approximated as zero (26). These methods have

been validated against invasive measures of ventricular pressure-volume loops (27,28).

**Dietary Assessment.** Dietary assessment was conducted using three-day diet records of a subset of participants. Dietary intake data were analyzed using FoodWorks version 7 using NUTTAB 2010 database (Xyris Software, Australia) for total energy (kcal), macronutrient, and dietary fiber intake.

#### Power Analyses

Baseline peak  $\dot{V}O_2$  was assumed to be  $22.0 \pm 6.0$  ml/kg per minute, and a 20% increase (effect size of 0.73) in the intervention group compared with the control participants would be clinically significant. Therefore, we required 41 participants in each group to have 90% power to detect a difference between groups ( $\alpha=0.05$ ); however, to account for drop out, we planned to recruit 90 patients.

#### Statistical Analyses

Analysis was performed on available data. Data were checked for normality using the Kolmogorov–Smirnov test. Results are expressed as mean  $\pm$  SD, median (interquartile range), or  $n$  (%) for categorical data. Baseline characteristics and change scores were compared between groups using independent  $t$  tests and chi-squared tests for




Figure 1. | Consolidated Standards of Reporting Trials diagram.

categorical variables. Pearson and Spearman correlations were performed between change in main outcome measure and other secondary measures. Data were analyzed using standard commercially available statistical software (SPSS version 18; PASW, Chicago, IL). Statistical significance was  $P \leq 0.05$ .

## Results

### Patient Characteristics

Ninety patients were screened between February 2008 and March 2010. Twelve percent ( $n=11$ ) of patients were identified as having abnormal wall motion suggestive of subclinical ischemia on ESE and were reviewed by a cardiologist before randomization. Nine patients were cleared, enrolled in the study, and completed the study without incident. In total, seven screened patients were not randomized, three did not meet inclusion criteria due to kidney function outside of range, one had significant inducible ischemia on baseline testing (suitable for medical management only and the patient's cardiologist declined the patient's participation), and three patients withdrew consent before randomization (including one patient requiring bypass surgery who no longer wished to participate), meaning that 83 patients were randomized. Of the 83 patients randomized, follow-up testing was completed in 72 patients (Figure 1).

The baseline characteristics of this patient group are summarized in Table 1 and there were no significant

group differences at baseline. Men comprised the majority of the patient group and the prevalence of type 2 diabetes was 42%. Diastolic dysfunction was evident in 61% of patients, whereas 8% of patients had evidence of systolic heart failure (Table 1). The lifestyle intervention group attended 70% of the supervised gym-based training and five additional visits (range, 0–10) during the home-based maintenance phase.

### Responses to Intervention


**Exercise Capacity.** At baseline, peak  $\dot{V}O_2$  ( $24.7 \pm 8.4$  ml/kg per minute in the lifestyle intervention group versus  $23.6 \pm 6.2$  ml/kg per minute in the control group) was similar between groups. Compared with normative values, 47% of the control group met their age-predicted exercise capacity and 41% in the lifestyle intervention group (Figure 2). The intervention was effective in improving peak  $\dot{V}O_2$  as evident by an 11% increase in the lifestyle intervention group and 1% decrease in the control (Figure 2). Furthermore, at 12 months, an additional 10 patients in the lifestyle intervention group met their age-predicted exercise capacity, which was significantly greater than controls ( $P=0.01$ ). The hemodynamic response to exercise was similar between groups at baseline. Maximal systolic BP decreased in both groups at 12 months; however, the change was significantly greater in the control group (Table 2).

**Cardiovascular Risk Factors.** Table 3 outlines changes in body habitus (weight, BMI, waist circumference) in

**Table 1. Baseline demographics, causes of kidney disease, myocardial status, and medication usage of patients randomized to lifestyle intervention or control groups that completed a 12-month follow-up visit**

|                                       | Lifestyle Intervention Group ( $n=36$ ) | Control Group ( $n=36$ ) | Lost to Follow-Up ( $n=11$ ) |
|---------------------------------------|---|--------------------------|------------------------------|
| Women                                 | 12 (33)                                 | 15 (42)                  | 6 (45)                       |
| Age (yr)                              | $60.2 \pm 9.7$                          | $62.0 \pm 8.4$           | $54.4 \pm 10.1$              |
| eGFR (ml/min per $1.73 \text{ m}^2$ ) | $38.4 \pm 8.8$                          | $39.4 \pm 8.9$           | $42.0 \pm 8.7$               |
| Cause of CKD                          |   |                          |                              |
| Diabetes                              | 9 (25)                                  | 11 (30)                  | 4 (36)                       |
| Renovascular                          | 6 (17)                                  | 5 (14)                   | —                            |
| GN                                    | 10 (28)                                 | 11 (30)                  | 3 (27)                       |
| APKD                                  | —                                       | 3 (8)                    | 1 (9)                        |
| Other                                 | 11 (30)                                 | 6 (17)                   | 3 (27)                       |
| Risk factors                          |   |                          |                              |
| Type 2 diabetes                       | 15 (42)                                 | 15 (42)                  | 3 (27)                       |
| Current smoker                        | 5 (14)                                  | 3 (8)                    | 3 (27)                       |
| Previous myocardial infarction        | 5 (14)                                  | 7 (24)                   | —                            |
| Systolic dysfunction                  | 4 (11)                                  | 2 (5)                    | —                            |
| Diastolic dysfunction                 | 19 (56)                                 | 25 (78)                  | 3 (27)                       |
| Medications                           |   |                          |                              |
| ACEi                                  | 17 (47)                                 | 19 (54)                  | 6 (55)                       |
| ARB                                   | 22 (61)                                 | 20 (56)                  | 5 (45)                       |
| $\beta$ blocker                       | 14 (39)                                 | 15 (42)                  | —                            |
| Calcium blocker                       | 10 (28)                                 | 17 (47)                  | 3 (27)                       |
| Platelet inhibitor                    | 19 (53)                                 | 14 (39)                  | 1 (9)                        |
| Statin                                | 23 (64)                                 | 24 (67)                  | 5 (45)                       |
| Insulin                               | 9 (25)                                  | 10 (28)                  | 1 (9)                        |

Values are mean  $\pm$  SD for normally distributed values, or  $n$  (%) for categorical variables. There were no significant differences ( $P > 0.05$  for all) between groups at baseline. eGFR, estimated GFR; APKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.



**Figure 2.** | Lifestyle intervention was associated with improved cardiorespiratory fitness. (A) Change in cardiorespiratory fitness after 12 months of intervention. Values are  $\Delta$  mean  $\pm$  SD and a significant difference between the lifestyle intervention and control groups. \* $P=0.01$ . (B) Percentage of patients to achieve age-predicted exercise capacity at baseline and 12 months. Values are the percentage of participants to achieve individual age-predicted exercise capacity. There was no statistical difference at baseline between the lifestyle intervention group and controls. Significantly more participants in the lifestyle intervention group at 12 months compared to baseline achieved age-predicted exercise capacity. \* $P=0.002$ . Significantly more participants in the lifestyle intervention group achieved age-predicted exercise capacity compared with the control group. # $P=0.01$  at 12 months. LI, lifestyle intervention.

response to the intervention, but not BP, lipids, or indicators of kidney function. Other electrolytes and indicators of kidney function, including phosphate and urine albumin/creatinine ratio, were unchanged by the intervention (data not included).

**Echocardiography.** Table 3 shows that there were no significant differences between echocardiographic characteristics at baseline. The intervention had a significant effect on diastolic tissue velocity ( $e'$ ) (Table 3), which increased by 20% in the lifestyle intervention group and decreased by 6% in the control group ( $P=0.001$ ).

**Arterial Compliance.** There were no significant baseline differences between any peripheral or central BP parameters, and arterial stiffness parameters and the intervention had no statistically significant effect on these parameters (Table 3).

**Ventricular-Vascular Interaction.** At baseline, the ventricular-vascular interaction parameters were similar between groups (Table 3). EA was significantly lower in the lifestyle intervention group at 12 months (Table 3).

### Dietary Analyses

Thirty-six participants completed diet records at baseline and follow-up (19 in the lifestyle intervention group and 17 in the control group). At baseline, total energy intake was

similar between groups ( $7422\pm 2872$  kJ in the lifestyle intervention group versus  $8002\pm 2553$  kJ in the control group). Macronutrient intake was not significantly different (% of total energy intake: protein lifestyle intervention,  $20\%\pm 4\%$  versus control,  $19\%\pm 5\%$ ; carbohydrate lifestyle intervention,  $41\%\pm 7\%$  versus control,  $43\%\pm 7\%$ ; fat lifestyle intervention,  $32\%\pm 6\%$  versus control  $31\%\pm 6\%$ ;) and fiber ( $20.6\pm 8.4$  g versus control,  $22.4\pm 9.6$  g) at baseline. There were no statistically significant differences between intervention and standard care groups for change in total energy intake or contribution of energy from macronutrients or fiber at 12 months.

### Correlates of Functional Change

Change in peak  $\dot{V}O_2$  was not correlated with age, sex, history of diabetes, subclinical ischemia, or history of myocardial infarction.  $\Delta$  peak  $\dot{V}O_2$  was associated with group allocation ( $r=0.31$ ,  $P=0.01$ ) and baseline peak  $\dot{V}O_2$  ( $r=-0.28$ ,  $P=0.03$ ),  $\Delta$  BMI ( $r=-0.36$ ,  $P=0.003$ ),  $\Delta$  waist circumference ( $r=-0.26$ ,  $P=0.04$ ), and  $\Delta$  body weight ( $r=-0.26$ ,  $P=0.003$ ).

### Discussion

This study is the largest exercise training study in CKD patients to date and was a predefined substudy of the

**Table 2.** Results from the maximal exercise test

|                                 | Lifestyle Intervention Group |                 | Control Group    |                 | P Value |
|---------------------------------|------------------------------|-----------------|------------------|-----------------|---------|
|                                 | Baseline                     | $\Delta$ 12 mo  | Baseline         | $\Delta$ 12 mo  |         |
| $\dot{V}O_2$ (ml/kg per minute) | 24.0 $\pm$ 8.27              | 2.8 $\pm$ 4.3   | 23.0 $\pm$ 6.3   | -0.4 $\pm$ 4.9  | 0.01    |
| Respiratory exchange quotient   | 1.06 $\pm$ 0.1               | 0.02 $\pm$ 0.1  | 1.04 $\pm$ 0.1   | -0.0 $\pm$ 0.1  | 0.22    |
| Max heart rate (bpm)            | 149.4 $\pm$ 27.1             | 1.5 $\pm$ 20.9  | 144.9 $\pm$ 19.3 | -3.7 $\pm$ 16.4 | 0.27    |
| Max systolic BP (mmHg)          | 178.4 $\pm$ 20.4             | -4.0 $\pm$ 27.7 | 191.9 $\pm$ 22.2 | 12.2 $\pm$ 27.2 | 0.02    |
| Max diastolic BP (mmHg)         | 81.6 $\pm$ 11.3              | -2.0 $\pm$ 13.0 | 86.3 $\pm$ 11.8  | -7.4 $\pm$ 11.3 | 0.08    |

Values are mean  $\pm$  SD for normally distributed values. P value indicates significant difference in  $\Delta$  between groups.

**Table 3. Baseline and changes in secondary outcome measures**

|   | Lifestyle Intervention Group |            | Control Group |            | P Value |
|---|------------------------------|------------|---------------|------------|---------|
|   | Baseline                     | Δ 12 mo    | Baseline      | Δ 12 mo    |         |
| <b>Cardiovascular risk factors</b>              |                              |            |               |            |         |
| Weight (kg)                                     | 92.6±22.5                    | −1.8±4.2   | 92.7±24.1     | 0.7±3.7    | 0.01    |
| Height (cm)                                     | 168.6±9.9                    | −0.0±0.8   | 167.3±9.0     | −0.2±1.0   | 0.51    |
| BMI (kg/m <sup>2</sup> )                        | 32.5±6.8                     | −0.6±1.4   | 33.0±8.0      | 0.3±1.4    | 0.01    |
| Waist (cm)                                      | 106.9±18.5                   | −1.4±5.5   | 107.6±17.9    | 1.6±5.0    | 0.01    |
| Serum creatinine (μmol/L)                       | 157.7±37.5                   | 4.6±30.0   | 150.1±33.3    | 3.4±26.6   | 0.85    |
| eGFR (ml/min per 1.73 m <sup>2</sup> )          | 38.4±8.8                     | −1.4±7.5   | 39.4±8.9      | 0.5±6.9    | 0.26    |
| Serum albumin (g/L)                             | 36.7±3.6                     | 0.7±3.8    | 37.8±3.4      | 1.0±2.4    | 0.70    |
| Fasting glucose (mmol/L)                        | 7.2±3.9                      | −1.0±3.2   | 6.5±2.6       | 0.3±2.8    | 0.07    |
| HbA1c (DM only, n=30) (%)                       | 7.3±1.2                      | 0.1±1.3    | 7.3±1.2       | 0.8±1.6    | 0.18    |
| Triglycerides (mmol/L)                          | 1.7±1.1                      | −0.0±0.7   | 1.8±1.0       | 0.2±1.3    | 0.42    |
| Total cholesterol (mmol/L)                      | 4.5±1.0                      | −0.2±1.0   | 4.4±1.1       | 0.0±1.0    | 0.48    |
| HDL cholesterol (mmol/L)                        | 1.2±0.5                      | 0.0±0.2    | 1.1±0.3       | 0.0±0.2    | 0.55    |
| LDL cholesterol (mmol/L)                        | 2.5±0.8                      | −0.2±0.9   | 2.5±1.0       | 0.0±0.8    | 0.29    |
| <b>Echocardiography</b>                         |                              |            |               |            |         |
| Mitral E wave (cm/s)                            | 67.7±17.2                    | 0.03±0.03  | 75.0±18.7     | −0.07±0.03 | 0.03    |
| Mitral A wave (cm/s)                            | 70.1±29.5                    | −0.02±0.02 | 76.4±23.5     | 0.04±0.02  | 0.07    |
| E/A   | 1.01±0.29                    | 0.11±0.07  | 1.05±0.36     | −0.17±0.04 | 0.002   |
| Deceleration time (m/s)                         | 240.6±52.2                   | −14.5±7.8  | 240.0±39.7    | 16.2±7.5   | 0.01    |
| LA Vol index (cm <sup>3</sup> /m <sup>2</sup> ) | 37.3±13.4                    | −1.0±7.4   | 40.2±11.5     | −3.0±9.3   | 0.65    |
| EDV index (ml/m <sup>2</sup> )                  | 45.0±14.9                    | −1.8±7.5   | 45.4±12.8     | 11.3±10.5  | <0.001  |
| ESV index (ml/m <sup>2</sup> )                  | 16.4±8.9                     | −0.7±3.9   | 14.9±5.9      | −3.0±4.4   | 0.03    |
| Ejection fraction (%)                           | 64±1                         | 3.1±1.3    | 68±1          | 1.2±1.5    | 0.19    |
| LV mass index (g/m <sup>2.7</sup> )             | 55.2±15.8                    | −3.9±2.1   | 54.6±12.9     | −3.0±2.9   | 0.98    |
| S' (cm/s)                                       | 6.13±1.2                     | 0.01±0.01  | 6.28±1.17     | 0.0±0.0    | 0.50    |
| e' (cm/s)                                       | 5.59±1.5                     | 0.75±1.16  | 5.88±1.4      | −0.47±1.0  | 0.001   |
| E/e'  | 13.6±9.4                     | −1.8±1.1   | 13.6±4.9      | −0.26±3.7  | 0.30    |
| Global longitudinal strain (%)                  | −18.4±3.9                    | −0.4±0.7   | −19.5±2.8     | 1.3±0.5    | 0.05    |
| Average global strain rate (s <sup>−1</sup> )   | −1.09±0.2                    | 0.1±0.0    | −1.12±0.19    | 0.0±0.0    | 0.45    |
| <b>Hemodynamic</b>                              |                              |            |               |            |         |
| Peripheral SBP (mmHg)                           | 128.8±16.1                   | −2.4±16.2  | 132.3±12.4    | −0.5±17.5  | 0.65    |
| Peripheral DBP (mmHg)                           | 74.9±8.1                     | 0.6±10.6   | 71.1±9.4      | 3.2±8.2    | 0.78    |
| Central SBP (mmHg)                              | 117.8±14.3                   | −1.9±14.6  | 119.5±12.8    | −0.4±17.0  | 0.71    |
| Central DBP (mmHg)                              | 75.9±8.2                     | 0.9±10.4   | 73.0±10.2     | 3.2±8.4    | 0.65    |
| Aix (%)   | 25.7±10.4                    | −0.2±8.5   | 24.5±8.1      | −1.0±8.5   | 0.73    |
| Heart rate (bpm)                                | 68.5±13.6                    | −2.4±9.9   | 66.0±9.3      | 1.1±8.5    | 0.18    |
| <b>Pulse wave velocity</b>                      |                              |            |               |            |         |
| Aortic (m/s)                                    | 9.2±2.1                      | 0.4±1.4    | 9.8±2.3       | 0.1±2.0    | 0.85    |
| <b>Ventricular-arterial interaction</b>         |                              |            |               |            |         |
| E <sub>A</sub> (mmHg/ml)                        | 2.3±0.7                      | 0.1±0.8    | 2.2±0.6       | 0.8±1.0    | 0.01    |
| E <sub>LV</sub> (mmHg/ml)                       | 4.8±2.8                      | 0.2±1.7    | 4.7±1.6       | 1.0±2.0    | 0.11    |
| E <sub>A</sub> /E <sub>LV</sub>                 | 0.57±0.2                     | −0.0±0.1   | 0.49±0.1      | 0.03±0.2   | 0.46    |

Values are mean ± SD for normally distributed values, or median (IQR) for non-normally distributed data. P value indicates significant difference in Δ between groups. BMI, body mass index; eGFR, estimated GFR; HbA1c, hemoglobin A1c; DM, diabetes mellitus; E/A, mitral E wave to mitral A wave ratio; LA, left atrial; EDV, end diastolic volume; ESV, end systolic volume; LV, left ventricular; S', systolic tissue velocity; e', diastolic tissue velocity; E/e', estimated left ventricle filling pressures; SBP, systolic BP; DBP, diastolic BP; Aix, augmentation index; E<sub>A</sub>, arterial elastance, E<sub>LV</sub>, LV end systolic elastance. VLDL, very low density lipoproteins.

ongoing LANDMARK III randomized controlled trial. The findings demonstrated that patients with moderate CKD randomized to receive an exercise and lifestyle intervention improved CRF, body composition, diastolic function, and preserved ventriculovascular coupling.

Our results are in agreement with previous reported findings from small studies (29–35) showing that exercise training is effective in improving CRF in patients with CKD. Uremic cardiomyopathy, comprising LV dilation,

hypertrophy, and impaired diastolic and systolic function, is common in late stage CKD and a strong predictor of adverse cardiovascular prognosis (8). Similar, but less severe abnormalities of LV function, as well as decreased arterial and ventricular elastance, exist in early CKD (11). The disturbances in myocardial function in CKD are likely multifactorial, with contributions from abnormal relaxation (due to myocardial disease and arterial disturbances leading to augmented wave reflection and increased

afterload) as well as fibrosis. The role of aerobic exercise training on cardiac function is controversial (12,36). A previous training study in patients with coronary heart disease and preserved systolic function reported that exercise lessened the severity of diastolic dysfunction (37). In this study, we have shown that exercise may be effective through improvement in  $e'$ .

This intervention ameliorated disturbances in the ventricular-arterial relationship. Disturbances in ventricular-arterial interaction, which are common in early stages of CKD (11), may be estimated indirectly by echocardiography (26,38). The matching between the LV and the arterial system at rest results in optimal transfer of blood from the LV to the periphery without excessive changes in pressure. The changes in arterial elastance were interesting. This finding suggests that better cardiac compensation with the maintenance of ventricular coupling ratio allows preservation of cardiac performance and may contribute to improved CRF in moderate CKD. It was of interest to note that there was deterioration in end systolic and end diastolic volumes in the control group that was abrogated in the lifestyle intervention group. Further work in this area is required.

We were unable to show any effect on arterial stiffness as measured by both aortic PWV and AIx. Improvement in arterial stiffness is associated with increased fitness (39,40) in the general population; however, the pathophysiology of vascular disease in CKD may be different and more resistant to change (41). Mustata *et al.* (35) demonstrated an improvement in arterial stiffness with exercise training in a small study of CKD patients. In contrast to our study, they did not use the standard measure of arterial stiffness (PWV) and included patients with more advanced CKD.

The findings from this study suggest that CKD patients, independent of preexisting comorbidities have the potential to improve CRF with exercise training. Improvement in CRF was associated with a small but significant improvement in body composition. The effect on clinical outcomes such as cardiovascular events needs to be tested in larger studies.

This study had a few limitations. We are unable to separate the individual components of the lifestyle intervention; however, the various components are likely to be complementary and integral to promoting successful lifestyle change. Changes in doses of medication were not recorded and it cannot be determined whether the lack of change in variables such as BP relates to modification of dose. However, the medication profile (number of patients taking different types of medication) did not significantly change in either group. We are unable to accurately quantify the amount of exercise performed by each participant in the lifestyle intervention group; however, the improvement in peak  $\dot{V}O_2$  suggests that the participants in the lifestyle intervention group were regularly exercising.

We observed unexpected changes in the end diastolic volume and ESV in the control group. The analysis of pro-brain natriuretic peptide may help explain these interesting results; however, it was beyond the scope of this analysis. Our assessment of ventricular-arterial interaction was based on noninvasive techniques. These techniques have been validated (26), but are less accurate than invasive methods. Furthermore, our study was not powered to

assess changes in arterial compliance although smaller studies have reported improvement with exercise training (35). No corrections for multiple comparisons of secondary outcomes have been made and the risk of a type I error may be increased. As such, results are exploratory and further studies are required.

In this study of patients with moderate CKD and well managed cardiovascular risk factors, randomization to the intervention led to significant improvements in CRF, body composition, and cardiovascular parameters at 12 months. Interestingly, improvement of CRF appeared to be more responsive to lifestyle intervention than dietary or weight change, despite the high prevalence of obesity in this group.

#### Acknowledgments

The authors thank research nurses Karen Sonnenburg and Lisa Ditterich for their time and effort in recruiting, testing, and maintaining participants in the trial.

This research was supported by the National Health and Medical Research Council-funded Centre for Clinical Research Excellence—Vascular and Metabolic Health of the University of Queensland, as well as the Department of Nephrology at Princess Alexandra Hospital.

The following abstracts originated from this work: Howden E, Coombes J, Petchey W, Isbel N. A one-year lifestyle intervention improves myocardial function and exercise capacity in patients with chronic kidney disease [Abstract]. *J Am Soc Nephrol* 22: 90A, 2011; and Howden EJ, Coombes JS, Leano R, Isbel NM, Marwick TH: Effect of exercise and lifestyle intervention on LV and vascular function in patients with chronic kidney disease: A randomized controlled trial [Abstract]. *Eur Heart J* 33[Suppl]: 515, 2012.

#### Disclosures

None.

#### References

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Cullerton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 108: 2154–2169, 2003
2. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. *Am Heart J* 144: 226–232, 2002
3. Padilla J, Krasnoff J, Da Silva M, Hsu CY, Frassetto L, Johansen KL, Painter P: Physical functioning in patients with chronic kidney disease. *J Nephrol* 21: 550–559, 2008
4. Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T: Physical activity and mortality in chronic kidney disease (NHANES III). *Clin J Am Soc Nephrol* 4: 1901–1906, 2009
5. Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK; American College of Sports Medicine: American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. *Med Sci Sports Exerc* 41: 459–471, 2009
6. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C; American College of Sports Medicine; American Heart Association: Physical activity and public health in older adults: Recommendation from the American College of Sports Medicine and the American Heart Association. *Circulation* 116: 1094–1105, 2007

7. Howden EJ, Fassett RG, Isbel NM, Coombes JS: Exercise training in chronic kidney disease patients. *Sports Med* 42: 473–488, 2012
8. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. *J Am Soc Nephrol* 5: 2024–2031, 1995
9. Edwards NC, Hirth A, Ferro CJ, Townend JN, Steeds RP: Sub-clinical abnormalities of left ventricular myocardial deformation in early-stage chronic kidney disease: The precursor of uremic cardiomyopathy? *J Am Soc Echocardiogr* 21: 1293–1298, 2008
10. Stanton T, Leano R, Marwick TH: Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. *Circ Cardiovasc Imaging* 2: 356–364, 2009
11. Edwards NC, Ferro CJ, Townend JN, Steeds RP: Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: A pattern resembling heart failure with preserved ejection fraction. *Heart* 94: 1038–1043, 2008
12. Levy WC, Cerqueira MD, Abrass IB, Schwartz RS, Stratton JR: Endurance exercise training augments diastolic filling at rest and during exercise in healthy young and older men. *Circulation* 88: 116–126, 1993
13. Belardinelli R, Georgiou D, Cianci G, Berman N, Ginzton L, Purcaro A: Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. *Circulation* 91: 2775–2784, 1995
14. Walsh JH, Bilsborough W, Maiorana A, Best M, O'Driscoll GJ, Taylor RR, Green DJ: Exercise training improves conduit vessel function in patients with coronary artery disease. *J Appl Physiol* 95: 20–25, 2003
15. National Heart Foundation of Australia: *Guide to Management of Hypertension 2008*. Sydney, Australia, National Heart Foundation of Australia, 2010
16. Johnson DW: Prevention of progression of kidney disease - CARI guidelines. *Aust Fam Physician* 36: 353, 2007
17. Borg GA: Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 14: 377–381, 1982
18. Ash S, Campbell K, MacLaughlin H, McCoy E, Chan M, Anderson K, Corke K, Dumont R, Lloyd L, Meade A, Montgomery-Johnson R, Tasker T, Thrift P, Trotter B: Evidence-based practice guidelines for the nutritional management of chronic kidney disease. *Nutr Diet* 63[Suppl 2]: S35–S45, 2006
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. *Ann Intern Med* 130: 461–470, 1999
20. Whaley M: *ACSM's Guidelines for Exercise Testing and Prescription*. Baltimore, Lippincott Williams & Wilkins, 2006
21. Klein AL, Burstow DJ, Tajik AJ, Zachariah PK, Bailey KR, Seward JB: Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. *Mayo Clin Proc* 69: 212–224, 1994
22. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL: How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 28: 2539–2550, 2007
23. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *J Am Soc Echocardiogr* 22: 107–133, 2009
24. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. *JAMA* 289: 194–202, 2003
25. Holland DJ, Sacre JW, McFarlane SJ, Coombes JS, Sharman JE: Pulse wave analysis is a reproducible technique for measuring central blood pressure during hemodynamic perturbations induced by exercise. *Am J Hypertens* 21: 1100–1106, 2008
26. Chantler PD, Lakatta EG, Najjar SS: Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. *J Appl Physiol* 105: 1342–1351, 2008
27. Chen CH, Fetis B, Nevo E, Rochitte CE, Chiou KR, Ding PA, Kawaguchi M, Kass DA: Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. *J Am Coll Cardiol* 38: 2028–2034, 2001
28. Cohen-Solal A, Caviezel B, Laperche T, Gourgon R: Effects of aging on left ventricular-arterial coupling in man: Assessment by means of arterial effective and left ventricular elastances. *J Hum Hypertens* 10: 111–116, 1996
29. Heiwe S, Tollbäck A, Clyne N: Twelve weeks of exercise training increases muscle function and walking capacity in elderly predialysis patients and healthy subjects. *Nephron* 88: 48–56, 2001
30. Clyne N, Ekholm J, Jogestrand T, Lins LE, Pehrsson SK: Effects of exercise training in predialytic uremic patients. *Nephron* 59: 84–89, 1991
31. Boyce ML, Robergs RA, Avasthi PS, Roldan C, Foster A, Montner P, Stark D, Nelson C: Exercise training by individuals with predialysis renal failure: Cardiorespiratory endurance, hypertension, and renal function. *Am J Kidney Dis* 30: 180–192, 1997
32. Pechter U, Ots M, Mesikepp S, Zilmer K, Kullisaar T, Vihalemm T, Zilmer M, Maaros J: Beneficial effects of water-based exercise in patients with chronic kidney disease. *Int J Rehabil Res* 26: 153–156, 2003
33. Toyama K, Sugiyama S, Oka H, Sumida H, Ogawa H: Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. *J Cardiol* 56: 142–146, 2010
34. Eidemak I, Haaber AB, Feldt-Rasmussen B, Kanstrup IL, Strandgaard S: Exercise training and the progression of chronic renal failure. *Nephron* 75: 36–40, 1997
35. Mustata S, Groeneveld S, Davidson W, Ford G, Kiland K, Manns B: Effects of exercise training on physical impairment, arterial stiffness and health-related quality of life in patients with chronic kidney disease: A pilot study. *Int Urol Nephrol* 43: 1133–1141, 2011
36. Finkelhor RS, Hanak LJ, Bahler RC: Left ventricular filling in endurance-trained subjects. *J Am Coll Cardiol* 8: 289–293, 1986
37. Yu CM, Li LS, Lam MF, Siu DC, Miu RK, Lau CP: Effect of a cardiac rehabilitation program on left ventricular diastolic function and its relationship to exercise capacity in patients with coronary heart disease: Experience from a randomized, controlled study. *Am Heart J* 147: e24, 2004
38. Chen CH, Nakayama M, Nevo E, Fetis BJ, Maughan WL, Kass DA: Coupled systolic-ventricular and vascular stiffening with age: Implications for pressure regulation and cardiac reserve in the elderly. *J Am Coll Cardiol* 32: 1221–1227, 1998
39. Vaitkevicius PV, Fleg JL, Engel JH, O'Connor FC, Wright JG, Lakatta LE, Yin FC, Lakatta EG: Effects of age and aerobic capacity on arterial stiffness in healthy adults. *Circulation* 88: 1456–1462, 1993
40. Tanaka H, Dinunno FA, Monahan KD, Clewenger CM, DeSouza CA, Seals DR: Aging, habitual exercise, and dynamic arterial compliance. *Circulation* 102: 1270–1275, 2000
41. Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, Boutouyrie P: Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. *Kidney Int* 69: 350–357, 2006

**Received:** October 3, 2012 **Accepted:** April 12, 2013

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

This article contains supplemental material online at <http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.10141012/-/DCSupplemental>.